A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight

Inclusion Criteria:

1. Male or female, age ≥18 years at the time of signing informed consent, and at leastthe legal age of consent in countries where it is >18 years

2. Body mass index (BMI) ≥30 kg/m^2 at screening, OR BMI ≥27 kg/m^2 with the presenceof at least one of the obesity-related complications (treated or untreated) e.g,:

• Hypertension (defined as repeated, i.e. at least 3 measurements in restingcondition, systolic blood pressure (SBP) values of ≥140 millimetre of mercury (mmHg) and/or diastolic blood pressure (DBP) values of ≥90 mmHg in the absenceof anti-hypertensive treatment, or intake of at least 1 anti-hypertensive drugto maintain a normotensive blood pressure)

• Dyslipidaemia (defined as at least 1 lipid-lowering treatment required tomaintain normal blood lipid levels, or low-density lipoprotein (LDL)cholesterol ≥160 mg/dL (≥4.1 mmol/L), or triglycerides ≥150 mg/dL (≥1.7mmol/L), or high-density lipoprotein (HDL) cholesterol <40 mg/dL (<1.0 mmol/L)for men or HDL cholesterol 50 mg/dL (<1.3 mmol/L) for women)

• Obstructive sleep apnoea

• Others.

3. History of at least one self-reported unsuccessful dietary effort to lose bodyweight.

Further inclusion criteria apply.

Exclusion Criteria:

1. Body weight change (self-reported) of >5% within 3 months before screening.

2. Treatment with any medication for the indication obesity within 3 months beforescreening.

3. Glycosylated haemoglobin A1c (HbA1c) ≥6.5% (≥48 mmol/mol) as measured by the centrallaboratory at screening.

4. History of type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM) ortreatment with glucose lowering agent started within 3 months before the screeningup to and including the randomisation visit.

5. Heart failure (HF) with New York Heart Association (NYHA) functional class IV.

6. Known clinically significant gastric emptying abnormality (e.g. severe diabeticgastroparesis or gastric outlet obstruction).

7. History of either chronic or acute pancreatitis or elevation of serum lipase orserum pancreatic amylase >2x upper limit of normal (ULN) as measured by the centrallaboratory at screening.

8. Personal or family history of medullary thyroid carcinoma (MTC) or multipleendocrine neoplasia syndrome type 2 (MEN 2).

Further exclusion criteria apply.